Advesya is developing therapies that target IL-1RAP, a protein upregulated in various cancers and autoimmune diseases, to enhance treatment efficacy. By focusing on this unique antigen, the company aims to address the challenges of treating difficult-to-manage malignancies and chronic inflammatory conditions.
Funding
$26M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers and autoimmune diseases are difficult to treat effectively due to the complex interplay of inflammatory cytokines and the limited availability of drug targets that are selectively expressed on diseased cells. Current therapies often lack specificity, leading to off-target effects and suboptimal patient outcomes.
Solution
Advesya is developing targeted therapies against IL-1RAP (Interleukin-1 Receptor Associated Protein), a protein upregulated in various cancers and autoimmune conditions but poorly expressed in healthy tissue. IL-1RAP acts as a crucial convergence point for IL-1-related cytokines involved in chronic inflammation, making it a compelling therapeutic target. Advesya's approach aims to enhance treatment efficacy by selectively targeting diseased cells expressing IL-1RAP, while minimizing impact on healthy tissues. Their pipeline includes antibody-drug conjugates (ADCs) and other modalities designed to disrupt IL-1RAP signaling and deliver cytotoxic payloads directly to target cells.
Target Audience
The primary target audience includes patients with cancers and autoimmune diseases where IL-1RAP is upregulated, as well as oncologists, rheumatologists, and other specialists treating these conditions.
Features
- CCTx-001: A therapeutic approach targeting IL-1RAP.
- ADV-101: A Topoisomerase I Inhibitor ADC targeting IL-1RAP, demonstrating preclinical efficacy in esophageal cancer models.
- Focus on disrupting IL-1RAP signaling to modulate inflammatory responses.
- Development of therapies designed to selectively target cells expressing IL-1RAP.